Arsen Osipov1,2,3, Alex B Blair1,2,4, Juliane Liberto1,2,3, Jianxin Wang1,2,3, Keyu Li1,2,3, Brian Herbst1,2,3, Yao Xu1,2,3, Shiqi Li1,2,3, Nan Niu1,2,3, Rufiaat Rashid1,2,3, Ding Ding1,2,4, Yanan Liu5, Zaiqi Wang5, Christopher L Wolfgang1,2,3,4, Richard A Burkhart1,2,3,4, Daniel Laheru1,2,3,4, Lei Zheng1,2,3,4. 1. The Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore 21287, MD, USA. 2. The Pancreatic Cancer Precision Medicine Center of Excellence Program, Johns Hopkins University School of Medicine, Baltimore 21287, MD, USA. 3. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore 21287, MD, USA. 4. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore 21287, MD, USA. 5. InxMed Shanghai, Shanghai 201202, China.
Abstract
Objective: Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy, due in large part to its resistance to conventional therapies, including radiotherapy (RT). Despite RT exerting a modest antitumor response, it has also been shown to promote an immunosuppressive tumor microenvironment. Previous studies demonstrated that focal adhesion kinase inhibitors (FAKi) in clinical development inhibit the infiltration of suppressive myeloid cells and T regulatory (T regs) cells, and subsequently enhance effector T cell infiltration. FAK inhibitors in clinical development have not been investigated in combination with RT in preclinical murine models or clinical studies. Thus, we investigated the impact of FAK inhibition on RT, its potential as an RT sensitizer and immunomodulator in a murine model of PDAC. Methods: We used a syngeneic orthotopic murine model to study the effect of FAKi on hypofractionated RT. Results: In this study we showed that IN10018, a small molecular FAKi, enhanced antitumor response to RT. Antitumor activity of the combination of FAKi and RT is T cell dependent. FAKi in combination with RT enhanced CD8+ T cell infiltration significantly in comparison to the radiation or FAKi treatment alone (P < 0.05). FAKi in combination with radiation inhibited the infiltration of granulocytes but enhanced the infiltration of macrophages and T regs in comparison with the radiation or FAKi treatment alone (P < 0.01). Conclusions: These results support the clinical development of FAKi as a radiosensitizer for PDAC and combining FAKi with RT to prime the tumor microenvironment of PDAC for immunotherapy. Copyright:
Objective: Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy, due in large part to its resistance to conventional therapies, including radiotherapy (RT). Despite RT exerting a modest antitumor response, it has also been shown to promote an immunosuppressive tumor microenvironment. Previous studies demonstrated that focal adhesion kinase inhibitors (FAKi) in clinical development inhibit the infiltration of suppressive myeloid cells and T regulatory (T regs) cells, and subsequently enhance effector T cell infiltration. FAK inhibitors in clinical development have not been investigated in combination with RT in preclinical murine models or clinical studies. Thus, we investigated the impact of FAK inhibition on RT, its potential as an RT sensitizer and immunomodulator in a murine model of PDAC. Methods: We used a syngeneic orthotopic murine model to study the effect of FAKi on hypofractionated RT. Results: In this study we showed that IN10018, a small molecular FAKi, enhanced antitumor response to RT. Antitumor activity of the combination of FAKi and RT is T cell dependent. FAKi in combination with RT enhanced CD8+ T cell infiltration significantly in comparison to the radiation or FAKi treatment alone (P < 0.05). FAKi in combination with radiation inhibited the infiltration of granulocytes but enhanced the infiltration of macrophages and T regs in comparison with the radiation or FAKi treatment alone (P < 0.01). Conclusions: These results support the clinical development of FAKi as a radiosensitizer for PDAC and combining FAKi with RT to prime the tumor microenvironment of PDAC for immunotherapy. Copyright:
Authors: Susannah Yovino; Bert W Maidment; Joseph M Herman; Naimish Pandya; Olga Goloubeva; Chris Wolfgang; Richard Schulick; Daniel Laheru; Nader Hanna; Richard Alexander; William F Regine Journal: Int J Radiat Oncol Biol Phys Date: 2012-01-25 Impact factor: 7.038
Authors: Amy J Wisdom; Cierra S Hong; Alexander J Lin; Yu Xiang; Daniel E Cooper; Jin Zhang; Eric S Xu; Hsuan-Cheng Kuo; Yvonne M Mowery; David J Carpenter; Kushal T Kadakia; Jonathon E Himes; Lixia Luo; Yan Ma; Nerissa Williams; Diana M Cardona; Malay Haldar; Yarui Diao; Stephanie Markovina; Julie K Schwarz; David G Kirsch Journal: Proc Natl Acad Sci U S A Date: 2019-08-28 Impact factor: 11.205
Authors: Sunil R Hingorani; Lifu Wang; Asha S Multani; Chelsea Combs; Therese B Deramaudt; Ralph H Hruban; Anil K Rustgi; Sandy Chang; David A Tuveson Journal: Cancer Cell Date: 2005-05 Impact factor: 31.743
Authors: Ke-Jing Tang; Jerfiz D Constanzo; Niranjan Venkateswaran; Margherita Melegari; Mariya Ilcheva; Julio C Morales; Ferdinandos Skoulidis; John V Heymach; David A Boothman; Pier Paolo Scaglioni Journal: Clin Cancer Res Date: 2016-05-24 Impact factor: 12.531
Authors: Alan Serrels; Tom Lund; Bryan Serrels; Adam Byron; Rhoanne C McPherson; Alexander von Kriegsheim; Laura Gómez-Cuadrado; Marta Canel; Morwenna Muir; Jennifer E Ring; Eleni Maniati; Andrew H Sims; Jonathan A Pachter; Valerie G Brunton; Nick Gilbert; Stephen M Anderton; Robert J B Nibbs; Margaret C Frame Journal: Cell Date: 2015-09-24 Impact factor: 41.582
Authors: Maja J A de Jonge; Neeltje Steeghs; Martijn P Lolkema; Sebastien J Hotte; Hal W Hirte; Diane A J van der Biessen; Albiruni R Abdul Razak; Filip Y F L De Vos; Remy B Verheijen; David Schnell; Linda C Pronk; Monique Jansen; Lillian L Siu Journal: Target Oncol Date: 2019-02 Impact factor: 4.493
Authors: Kenji Fujiwara; May Tun Saung; Hao Jing; Brian Herbst; MacKenzie Zarecki; Stephen Muth; Annie Wu; Elaine Bigelow; Linda Chen; Keyu Li; Neolle Jurcak; Alex B Blair; Ding Ding; Michael Wichroski; Jordan Blum; Nathan Cheadle; Jennifer Koenitzer; Lei Zheng Journal: J Immunother Cancer Date: 2020-07 Impact factor: 13.751
Authors: Kendelle J Murphy; Jessie Zhu; Michael Trpceski; Brooke A Pereira; Paul Timpson; David Herrmann Journal: Biochem Soc Trans Date: 2022-08-31 Impact factor: 4.919